



**NEWS RELEASE – for immediate release**

Source: Patheon Inc.  
Website: [www.patheon.com](http://www.patheon.com)

**PATHEON SIGNS STRATEGIC ALLIANCE AGREEMENT WITH KEMWELL**

**Expanding Capabilities to India**

**Zug, Switzerland, (April 1, 2009)** – Patheon (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry today announced it has entered into a strategic alliance agreement with Kemwell Pvt. Limited, a leading provider of formulations contract manufacturing and development services based in Bangalore, India.

The alliance allows Patheon and Kemwell to refer and market each others' services to clients to better meet their respective client's requirements. The alliance is effective immediately and full promotion by Patheon's business development units is expected by mid-year.

"This alliance gives us more flexibility in our service offering. With Kemwell's GMP facility and expertise, we can offer our clients low volume, low cost solutions in solid, semi-solid and liquid dosage form manufacturing, and a full range of formulation and CMC-related development services from a new base in India," said Wes Wheeler, Chief Executive Officer and President of Patheon Inc.

"Patheon's aseptic and high-potent manufacturing expertise brings an important capability to Kemwell's portfolio of services, " said Anurag Bagaria, Vice-President Business Development of Kemwell Pvt. Ltd. "We look forward to actively and cooperatively meeting and exceeding our respective client's requirements".

## ABOUT KEMWELL

Bangalore-based Kemwell Pvt. Ltd. ([www.kemwellpharma.com](http://www.kemwellpharma.com)) is a leading provider of formulations contract manufacturing and development services for multinational pharmaceutical companies for over 20 years. From facilities in India and Sweden, Kemwell manufactures tablets, capsules, liquid orals, external drops, ointments, gels and creams. Kemwell's customers include 5 of the top 10 pharmaceutical companies in the world, manufacturing 5 of the top 10 brands in India. Kemwell's Pharmaceutical Development Unit provides services in clinical manufacturing and packaging, formulation and analytical development, stability studies, regulatory documentation etc. With a 100% commitment to pure play contract manufacturing, Kemwell has no branded products of its own in the market, thereby avoiding any conflict of interests with its customers.

## ABOUT PATHEON

Patheon Inc. (TSX:PTI; [www.patheon.com](http://www.patheon.com)) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic™ programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API. Patheon's integrated development and manufacturing network of 10 facilities, and 6 development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world.

### Caution Concerning Forward-Looking Statements

*This news release may contain forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities. These statements are made in the context of the risks and uncertainties that are outlined in the Company's public documents, which can be accessed on our website at [www.patheon.com](http://www.patheon.com) or on SEDAR at [www.sedar.com](http://www.sedar.com).*

### Contacts:

Mr. Wes Wheeler  
President & Chief Executive Officer  
Tel: (919) 226-3200  
Email: [wes.wheeler@patheon.com](mailto:wes.wheeler@patheon.com)

Ms. Jean Treadwell  
Investor Relations  
Tel: (905) 816-8344  
Email: [jean.treadwell@patheon.com](mailto:jean.treadwell@patheon.com)

Mr. Eric Evans  
Chief Financial Officer  
Tel: (919) 226-3204  
Email: [eric.evans@patheon.com](mailto:eric.evans@patheon.com)

Mr. Anurag Bagaria  
VP, Business Development, Kemwell  
Tel: +91-80-3928-6200  
Email: [anurag.bagaria@kemwellpharma.com](mailto:anurag.bagaria@kemwellpharma.com)